SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

HONG KONG SAR - Media OutReach - 4 July 2022 - A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC's Omicron-specific COVID-19 inactivated vaccine used as a booster shot in healthy adults, in anticipation of providing scientific evidence for future immunization...

Related Keywords

China ,Gleneagles Hospital ,Singapore General ,Singapore ,Hong Kong ,University Of Hong Kong ,Hong Kong General ,Kenneth Tsang ,Henry Yau ,Hong Kong Gleneagles ,Asia Pacific ,Dean Of Department Medicine ,International Business Development ,University Of Hong Kong Hkumed ,Biotech Ltd ,Sinovac Biotech Ltd ,School Of Clinical Medicine ,University Of Hong Kong Clinical Trials Centre ,Clinical Trials Centre ,Department Of Medicine ,Gleneagles Hospital Hong Kong ,Hong Kong Clinical Trials Centre ,Ivan Hung Fan Ngai ,Helen Lieh Professor ,Health Sciences Pedagogy ,Clinical Professor ,Infectious Diseases ,Clinical Medicine ,Assistant Dean ,Cheryl Law ,International Business Development Director ,Managing Director ,Hong Kong Clinical Trials ,Professor Ivan Hung Fan Ngai ,Professor Ivan Hung ,Review Board ,Poisons Board ,Trials Centre ,Wong Chuk Hang ,Hong Kong Island South ,